Hurkmanns et al. found that lower granzyme B levels in patients with metastatic cancer favored tumor growth by halting the antitumor immunity response by cytotoxic immune cells (Hurkmans et al., 2020). The gene discussed is GZMB; the disease is metastatic malignant neoplasm.